Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Upcoming ...

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Dec 13, 2022 2:36pm

263 Views

Post# 35169148

RE:RE:RE:RE:Upcoming ...

nobeard wrote: Has there been any mention of Nunance and how they might fit into this?

Yes - a couple points on Nuance

First, Nuance will likely own all rights to OTENA ... be it acute and/or chronic

Second, there are some wording issues in the agreement for ATE/Nuance to figure out

ATE wants Nuance as a partner so they will figure it out.

----------------

Comments from Dan on this - one of the last two webinars (can't remember which one).

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks